Cargando…
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients
Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (<2000 IU/mL, detection limit of 10 IU/mL) after 48 weeks of antiviral treatment. Effective antiviral therapies for chronic hepatitis B (CHB) patients, such as entecavir (ETV), ten...
Autores principales: | Zhang, Qian, Cai, Da-Chuan, Hu, Peng, Ren, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668013/ https://www.ncbi.nlm.nih.gov/pubmed/34759219 http://dx.doi.org/10.1097/CM9.0000000000001793 |
Ejemplares similares
-
Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease
por: Zhang, Qian, et al.
Publicado: (2021) -
Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs
por: Han, Jiajia, et al.
Publicado: (2023) -
Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs
por: Xia, Ziqiang, et al.
Publicado: (2021) -
Adherence to Treatment with Oral Nucleoside/Nucleotide Analogs in Patients with Chronic Hepatitis B
por: Ozyigitoglu, Derya, et al.
Publicado: (2022) -
How does low-level viremia affect the prognosis of patients with chronic hepatitis B?
por: Lee, Hye Won, et al.
Publicado: (2020)